Latest Margin Expansion News

Collins Foods has reported a robust 6.7% increase in total sales for the first 18 weeks of FY26, driven by strong same-store sales growth in Australia, the Netherlands, and Germany. The company reaffirms its optimistic profit guidance amid ongoing expansion and operational improvements.

Pure Foods Tasmania has completed a strongly oversubscribed $1.76 million capital raise and reported improved preliminary FY25 results, signaling progress in its turnaround strategy.

Clime Investment Management has reported a strong FY25 profit turnaround, posting $2.1 million pretax and amortisation profit and declaring a fully franked dividend. The company outlines ambitious growth and margin targets for FY26 amid strategic restructuring and technology investments.

OMG Group Limited reported a robust 63.3% revenue increase to $4.13 million in FY2025, driven by strategic acquisitions and expanded retail partnerships. The company also narrowed its losses by 29%, setting the stage for sustained growth in FY2026.

8common Limited reported a significant narrowing of its net loss for FY25 alongside a 16% growth in SaaS revenue and improved gross margins, positioning the company for profitability in FY26.

Prophecy International Holdings reported a 5% revenue decline and a 53% increase in net loss for FY25, while advancing key product developments and announcing a transformative merger with Complexica.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.6 million for the first half of 2025, driven by Healthy Chef and Hemp Foods Australia, alongside improved gross margins. However, integration expenses weighed on profitability, resulting in an adjusted EBITDA loss of $2.2 million.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.

Carbonxt Group Limited reported a 7.1% revenue increase and a significant EBITDA improvement in FY25, while commissioning delays at its Kentucky facility temper near-term optimism.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Mayne Pharma Group Limited reported a robust FY25 with a 5% revenue increase to A$408.1 million and a 105% surge in underlying EBITDA, driven by strong growth in Women’s Health and strategic acquisitions in Dermatology.

Mayne Pharma reported a robust 5% revenue increase to $408.1 million and more than doubled its underlying EBITDA to $47 million in FY25, driven by strong Women’s Health sales and strategic acquisitions in Dermatology.